Drugs / FB102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07623057 | Jun 2026 → Feb 2027 expected | — | Forte Biosciences, Inc. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06982963 | Aug 2025 → Feb 2027 expected | celiac disease | Forte Biosciences, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07205159 Comparator | Oct 2025 → Mar 2027 expected | alopecia areata | Forte Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06905873 Comparator | Mar 2025 → Dec 2026 expected | vitiligo | Forte Biosciences, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | argenx | argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline argenx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FB102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06982963 ↗ |
| Route | Intravenous | “Route of administration- Intravenous (IV)” NCT06905873 ↗ |